



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

NF2 (h4): 293T Lysate: sc-172636

BACKGROUND

Neurofibromatosis type 2 (NF2) is a dominantly inherited disorder characterized by the occurrence of bilateral vestibular schwannomas and other central nervous system tumors, including multiple meningiomas. NF2 occurs in about 1 of 40,000 live births. The NF2 gene is highly penetrant; NF2-affected individuals have a 95% chance of developing bilateral vestibular schwannomas. NF2 is distinct from NF1, which is characterized by an incidence of 1 in 4,000, maps to chromosome 17 and encodes a protein designated Neurofibromin, which is a large protein with a GAP domain. Genetic linkage studies of both sporadic and familial tumors suggest that NF2 is caused by inactivation of a tumor suppressor gene that maps on chromosome 22q12.2 and encodes a 595 amino acid protein whose function appears to be mediated by interaction with the cytoskeleton.

REFERENCES

1. Rouleau, G.A., et al. 1990. Flanking markers bracket the neurofibromatosis type 2 (NF2) gene on chromosome 22. *Am. J. Hum. Genet.* 46: 323-328.
2. Narod, S.A., et al. 1992. Neurofibromatosis type 2 appears to be a genetically homogeneous disease. *Am. J. Hum. Genet.* 51: 486-496.
3. Evans, D.G.R., et al. 1992. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness and confirmation of maternal transmission effect on severity. *J. Med. Genet.* 29: 841-846.
4. DeClue, J.E., et al. 1992. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. *Cell* 69: 265-273.
5. Trofatter, J.A., et al. 1993. A novel Moesin-, Ezrin-, Radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. *Cell* 72: 791-800.
6. Kinzler, K.W., et al. 1993. A gene for neurofibromatosis 2. *Nature* 363: 495-496.
7. Rouleau, G.A., et al. 1993. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. *Nature* 363: 515-521.

CHROMOSOMAL LOCATION

Genetic locus: NF2 (human) mapping to 22q12.2.

PRODUCT

NF2 (h4): 293T Lysate represents a lysate of human NF2 transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

APPLICATIONS

NF2 (h4): 293T Lysate is suitable as a Western Blotting positive control for human reactive NF2 antibodies. Recommended use: 10-20 µl per lane.


Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

NF2 (E-2): sc-55574 is recommended as a positive control antibody for Western Blot analysis of enhanced human NF2 expression in NF2 transfected 293T cells (starting dilution 1:100, dilution range 1:100-1:1,000).

RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended:
 1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048.

DATA



NF2 (E-2): sc-55574. Western blot analysis of NF2 expression in non-transfected: sc-117752 (A) and human NF2 transfected: sc-172636 (B) 293T whole cell lysates.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.